Manuel Vicente Sánchez Chapado-rekin lankidetzan egindako argitalpenak (40)

2023

  1. Resistance to 2-Hydroxy-Flutamide in Prostate Cancer Cells Is Associated with the Downregulation of Phosphatidylcholine Biosynthesis and Epigenetic Modifications

    International Journal of Molecular Sciences, Vol. 24, Núm. 21

2022

  1. A Highly Sensitive Immunoassay for Determination of Immune Response to SARS-CoV-2 in Capillary Blood Samples

    Biomedicines, Vol. 10, Núm. 11

2021

  1. Increase in ischemia-modified albumin and pregnancy-associated plasma protein-a in covid-19 patients

    Journal of Clinical Medicine, Vol. 10, Núm. 23

2018

  1. Does [-2]Pro-Prostate Specific Antigen Meet the Criteria to Justify Its Inclusion in the Clinical Decision-Making Process?

    Urologia Internationalis, Vol. 100, Núm. 2, pp. 146-154

  2. Validación del índice de salud prostática en un modelo predictivo de cáncer de próstata

    Actas Urologicas Espanolas, Vol. 42, Núm. 1, pp. 25-32

2017

  1. A DNA hypermethylation profile reveals new potential biomarkers for the evaluation of prognosis in urothelial bladder cancer

    APMIS, Vol. 125, Núm. 9, pp. 787-796

2016

  1. A DNA Hypermethylation Profile Independently Predicts Biochemical Recurrence Following Radical Prostatectomy

    Urologia Internationalis, Vol. 97, Núm. 1, pp. 16-25

  2. Anti-proliferative and pro-apoptotic effects of GHRH antagonists in prostate cancer

    Oncotarget, Vol. 7, Núm. 32, pp. 52195-52206

  3. Development of Castration Resistant Prostate Cancer can be Predicted by a DNA Hypermethylation Profile

    Journal of Urology, Vol. 195, Núm. 3, pp. 619-626

  4. Survival predictors in patients with prostate adenocarcinoma with hormonal blockade

    Pathology Research and Practice, Vol. 212, Núm. 10, pp. 899-903

2015

  1. VIP induces NF-κB1-nuclear localisation through different signalling pathways in human tumour and non-tumour prostate cells

    Cellular Signalling, Vol. 27, Núm. 2, pp. 236-244

2014

  1. A DNA hypermethylation profile reveals new potential biomarkers for prostate cancer diagnosis and prognosis

    Prostate, Vol. 74, Núm. 12, pp. 1171-1182

  2. Prostate anatomy in motheaten viable (mev) mice with mutations in the protein tyrosine phosphatase SHP-1

    Actas Urologicas Espanolas, Vol. 38, Núm. 7, pp. 438-444

  3. Signalling pathways involved in antitumoral effects of VIP in human renal cell carcinoma A498 cells: VIP induction of p53 expression

    International Journal of Biochemistry and Cell Biology, Vol. 53, pp. 295-301

2013

  1. Antitumoral effects of vasoactive intestinal peptide in human renal cell carcinoma xenografts in athymic nude mice

    Cancer Letters, Vol. 336, Núm. 1, pp. 196-203

  2. The study of DNA methylation in urological cancer: Present and future

    Actas Urologicas Espanolas

  3. Vasoactive intestinal peptide induces oxidative stress and suppresses metastatic potential in human clear cell renal cell carcinoma

    Molecular and Cellular Endocrinology, Vol. 365, Núm. 2, pp. 212-222

2012

  1. Antioxidant activity of vasoactive intestinal peptide in HK2 human renal cells

    Peptides, Vol. 38, Núm. 2, pp. 275-281

  2. Overexpression of vasoactive intestinal peptide receptors and cyclooxygenase-2 in human prostate cancer. Analysis of potential prognostic relevance

    Histology and Histopathology, Vol. 27, Núm. 8, pp. 1093-1101

  3. Vasoactive intestinal peptide (VIP) inhibits human renal cell carcinoma proliferation

    Biochimica et Biophysica Acta - Molecular Cell Research, Vol. 1823, Núm. 10, pp. 1676-1685